Interestingly, CASP8 showed similarly increased mutation rate both in early- and late-stage cancers with TMD, while HRAS mutations appeared linked with TMD only in late-stage tumors – pointing toward a timing specificity of TMD-linked evolutionary pressures (Supplementary Figure 14). This evidence concerns the gene CASP8 and cancer.